[Federal Register Volume 71, Number 156 (Monday, August 14, 2006)]
[Notices]
[Pages 46495-46496]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 06-6871]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Recombinant Antibodies 
and Immunoconjugates Targeted to CD-22 Bearing Cells and Tumors

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR Part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in U.S. 
Patent Application No. 09/381,497, filed September 20, 1999, entitled 
``Recombinant Antibodies and Immunoconjugates Targeted to CD-22 Bearing 
Cells and Tumors'' [E-059-1997/0-US-07]; European Patent Application 
No. 98912977.0, filed October 13, 1999, entitled ``Recombinant 
Antibodies and Immunoconjugates Targeted to CD-22 Bearing Cells and 
Tumors'' [E-059-1997/0-EP-05]; Japanese Patent Application No. 10-
540812, filed March 19, 1998, entitled ``Recombinant Antibodies and 
Immunoconjugates Targeted to CD-22 Bearing Cells and Tumors'' [E-059-
1997/0-JP-06]; Australian Patent No. 740904, issued on February 28, 
2002, entitled ``Recombinant Antibodies and Immunoconjugates Targeted 
to CD-22 Bearing Cells and Tumors'' [E-059-1997/0-AU-03]; and Canadian 
Patent Application No. 2284665, filed March 19, 1998, entitled 
``Recombinant Antibodies and Immunoconjugates Targeted to CD-22 Bearing 
Cells and Tumors'' [E-059-1997/0-CA-04]; to Cambridge Antibody 
Technology, Ltd., which has offices in Cambridge, United Kingdom. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of the BL22 and HA22 and 
variants thereof as claimed in the licensed patent rights for the 
treatment of hematologic malignancies.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 13, 2006 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jesse S. Kindra, J.D., M.S., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone (301) 435-5559; Facsimile: (301) 402-0220; E-
mail: <a href="/cdn-cgi/l/email-protection#fa9193949e889b90ba979b9396d4949392d49d958c"><span class="__cf_email__" data-cfemail="87eceee9e3f5e6edc7eae6eeeba9e9eeefa9e0e8f1">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: This technology is a family of two (2) 
immunoconjugates, each consisting of an anti-CD-22 antibody coupled to 
a killing moiety, specifically pseudomonas exotoxin (PE38). The 
immunotoxins are both targeted towards CD-22, and may be useful as 
therapeutic agents for the treatment of leukemias, lymphomas and 
autoimmune diseases. Further, BL22 has shown success in early clinical 
trials.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.


[[Page 46496]]


    Dated: July 28, 2006.
Steven Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 06-6871 Filed 8-11-06; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>